Coloplast A/S Series B,

Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
  • TickerCOLO B
  • ISINDK0060448595
  • ExchangeNasdaq Nordic Copenhagen
  • SectorHealth Care Equipment & Services
  • CountryDenmark

Analysts

Alexander Aukner ...
  • Antti Kansanen
  • Håkon Astrup
  • Helge André Martinsen
  • Jon Masdal
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Paul Harper
  • Rune Majlund Dahl

Northern Lights

Rune Majlund Dahl

Coloplast (Buy, TP: DKK700.00) - 2018/19 another investment year

With management having stated several times that it aims and invests for the high end of its 7–9% long-term organic growth guidance, we were disappointed with its c8% guidance, indicating to us that the investments are not benefiting as fast as we had hoped. We have confidence in the new products but the ramp up to get scale and its investments will hit the margin. We retain our BUY but have cut our target price to DKK700 (745).

Debbie Wang

Morningstar | Coloplast Delivers Another Solid Quarter, but Shares React to CEO's Retirement News

Coloplast reported another quarter of solid performance that held no surprises, and we’re leaving our fair value estimate of DKK 610 unchanged. With the fiscal fourth quarter in the books, Coloplast hit our full-year top- and bottom-line projections nearly on the nose. We remain fans of this narrow-moat firm that consistently outpaces market growth in its key product areas—ostomy and continence care—through an emphasis on innovation and execution. Ostomy and continence care wrapped up the fiscal year with 9% and 8% organic growth, respectively, which is substantially above the mid-single-digit...

Debbie Wang

Coloplast Delivers Another Solid Quarter, but Shares React to CEO's Retirement News

Coloplast reported another quarter of solid performance that held no surprises, and we’re leaving our fair value estimate of DKK 610 unchanged. With the fiscal fourth quarter in the books, Coloplast hit our full-year top- and bottom-line projections nearly on the nose. We remain fans of this narrow-moat firm that consistently outpaces market growth in its key product areas—ostomy and continence care—through an emphasis on innovation and execution. Ostomy and continence care wrapped up the fiscal...

Rune Majlund Dahl

Coloplast (Buy, TP: DKK745.00) - Weak 2018/19 guidance

With c8% organic revenue growth and an EBIT margin of c33% in Q4, Coloplast reached its full-year guidance of c8% and c32%, respectively. The 2018/19 guidance of c8% organic revenue growth and an EBIT margin in constant currency of c30–31% is below what we and consensus expected and does not reflect the high end of the long-term guidance as previously communicated

Rune Majlund Dahl

Coloplast (Buy, TP: DKK745.00) - Set to take growth to the next level

We expect Coloplast to meet its 2017/18 organic guidance, implying c8% organic growth YOY and a c33.1% EBIT margin in Q4 (results due around noon CET on 1 November). We expect the 2018/19 organic growth guidance to be at the high end of the long-term range at 8–9%, driven by the US and emerging markets, as increased investment yields additional growth. We reiterate our BUY and DKK745 target price.

A director bought 38,300 shares at 521.960DKK and

A director at Coloplast As bought 38,300 shares at 521.960DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Alexander Aukner ...
  • Antti Kansanen
  • Håkon Astrup
  • Helge André Martinsen
  • Jon Masdal
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Paul Harper
  • Rune Majlund Dahl

Northern Lights

Alexander Aukner ...
  • Antti Kansanen
  • Frank Maaø
  • Mattias Montgomery
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Mattias Holmberg ...
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Christer Magnergård ...
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Eivind Sars Veddeng ...
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

null

Nurhayati Wan

Coloplast

null

Nurhayati Wan

Coloplast

GlobalData Department

Coloplast AS (COLO B) - Medical Equipment - Deals and Alliances Profile

Summary Coloplast A/S (Coloplast) is a medical device company that offers products and services for ostomy care, urology care, continence care, and skin and wound care. Its major products include ostomy bags; urisheaths; urine bags; catheters; anal irrigation systems; vaginal sling products; advanced foam dressings and hydrocolloid dressings for infected, non-infected and painful wounds; cleansers; moisturizers; skin protectants; anti-fungals; and hand cleansers. It also offers a wide range of disposable products to support endourological and percutaneous procedures, prostate disorders, lapar...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 07/12/2017

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.Under ITEMS 5a-5g, the (re-)election of the board of directors is proposed.Under ITEM 5a, it is proposed to re-appoint Mr. Michael Pram Rasmussen as Chairman of the board of directors. Although Mr. Pram Rasmussen is deemed independent, ECGS has various other concerns over his re-appointment. Therefore, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.Under ITEM...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch